{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:43:12Z","timestamp":1781134992899,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.radonc.2014.06.009","type":"journal-article","created":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T12:30:25Z","timestamp":1404563425000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy"],"prefix":"10.1016","volume":"112","clinical-trial-number":[{"clinical-trial-number":"nct01578902","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Evelyn","family":"Elias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Deabreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D\u2019Alimonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perakaa","family":"Sethukavalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mamedov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2014.06.009_b0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2011.02.013","article-title":"Development of indicators of the quality of radiotherapy for localized prostate cancer","volume":"99","author":"Danielson","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2014.06.009_b0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clon.2012.05.002","article-title":"Intensity-modulated radiotherapy in the treatment of prostate cancer","volume":"24","author":"Bauman","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0020","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2=1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2014.06.009_b0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2014.06.009_b0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.radonc.2014.06.009_b0040","unstructured":"ASTRO Model Policies. Stereotactic Body Radiation Therapy (SBRT). 2013 Apr 17, 2013 [cited 2013 August]; Available from: https:\/\/HYPERLINK \u201chttp:\/\/www.astro.org\/uploadedFiles\/Main_Site\/Practice_Management\/Reimbursement\/2013HPcoding%20guidelines_SBRT_Final.pdf\u201dwww.astro.org\/uploadedFiles\/Main_Site\/Practice_Management\/Reimbursement\/2013HPcoding%20guidelines_SBRT_Final.pdf."},{"key":"10.1016\/j.radonc.2014.06.009_b0045","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ijrobp.2010.04.046","article-title":"Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer","volume":"80","author":"Morton","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2014.06.009_b0050","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials. The CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2014.06.009_b0055","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials","volume":"87","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2014.06.009_b0060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-717X-8-118","article-title":"Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6years","volume":"8","author":"Katz","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.clon.2008.08.006","article-title":"Phase I\/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3","volume":"20","author":"Tang","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0070","first-page":"1314","article-title":"Controversies in prostate cancer radiotherapy: consensus development","volume":"8","author":"Lukka","year":"2001","journal-title":"Can J Urol"},{"key":"10.1016\/j.radonc.2014.06.009_b0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1999.17.1.168","article-title":"Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer","volume":"17","author":"D\u2019Amico","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0080","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2014.06.009_b0085","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2014.06.009_b0090","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0095","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijrobp.2004.09.051","article-title":"Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer","volume":"62","author":"Cheung","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2014.06.009_b0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-717X-4-50","article-title":"Image guided dose escalated prostate radiotherapy: still room to improve","volume":"4","author":"Martin","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2014.06.009_b0105","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2014.06.009_b0110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2014.06.009_b0115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.radonc.2014.06.009_b0120","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2014.06.009_b0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s11136-007-9223-3","article-title":"How can quality of life researchers make their work more useful to health workers and their patients?","volume":"16","author":"Guyatt","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.radonc.2014.06.009_b0130","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2014.06.009_b0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1748-717X-9-52","article-title":"Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer","volume":"9","author":"Bhattasali","year":"2014","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.radonc.2014.06.009_b0145","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2009.07.1748","article-title":"Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial","volume":"78","author":"Wiegner","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814014002667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814014002667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T12:52:21Z","timestamp":1565614341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814014002667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0167814014002667"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2014.06.009","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2014.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}